Publication Name	World Journal of Clinical Cases
Manuscript ID	97881
Country	Egypt

Received	2024-06-11 14:29
Peer-Review Started	2024-06-11 14:29
To Make the First Decision
Return for Revision	2024-07-25 02:24
Revised	2024-07-25 20:28
Second Decision	2024-07-31 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-07-31 08:51
Articles in Press	2024-07-31 08:51
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-13 02:17
Typeset the Manuscript	2024-08-22 14:11
Publish the Manuscript Online	2024-09-24 02:54

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Editorial
Article Title	Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression
Manuscript Source	Invited Manuscript
All Author List	Basma M E Mohamed and Mohamed E A Abdelrahim
ORCID	Author(s) ORCID Number Mohamed E A Abdelrahim http://orcid.org/0000-0003-0227-8404
Funding Agency and Grant Number
Corresponding Author	Mohamed E A Abdelrahim, PhD, Professor, Department of Clinical Pharmacy, Faculty of pharmacy, Beni-suef University, Beni suef 23343, Egypt. mohamed.abdelrahim@pharm.bsu.edu.eg
Key Words	Idiopathic pulmonary fibrosis; Pirfenidone; Pirfenidone anti-inflammatory mechanism; Pirfenidone anti-fibrotic activity
Core Tip	Pirfenidone is commonly used to treat idiopathic pulmonary fibrosis (IPF) in its early stages, but it has also demonstrated a notable impact on the disease in its advanced stages. In individuals with IPF who had substantial deterioration of their lung function, pirfenidone had a similar degree of efficacy. Pirfenidone appears to be safe when given to patients with advanced IPF, and it has a favorable benefit-risk profile, making it an appropriate treatment option for patients with idiopathic pulmonary fibrosis.
Publish Date	2024-09-24 02:54
Citation	<p>Mohamed BME, Abdelrahim MEA. Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression. <i>World J Clin Cases</i> 2024; 12(32): 6538-6542</p>
URL	https://www.wjgnet.com/2307-8960/full/v12/i32/6538.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i32.6538

Full Article (PDF)	WJCC-12-6538-with-cover.pdf
Manuscript File	97881_Auto_Edited_055842.docx
Answering Reviewers	97881-answering-reviewers.pdf
Audio Core Tip	97881-audio.wma
Conflict-of-Interest Disclosure Form	97881-conflict-of-interest-statement.pdf
Copyright License Agreement	97881-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	97881-non-native-speakers.pdf
Peer-review Report	97881-peer-reviews.pdf
Scientific Misconduct Check	97881-scientific-misconduct-check.png
Scientific Editor Work List	97881-scientific-editor-work-list.pdf
CrossCheck Report	97881-crosscheck-report.pdf
CrossCheck Report	97881-crosscheck-report.png